A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes

Rafiee, Mohammad; Abbasi, Mehrshad; Rafieemehr, Hassan; Mirzaeian, Amin; Barzegar, Mohyedin; Amiri, Vahid; Shahsavan, Shaghayegh; Mohammadi, Mohammad Hossein

doi:10.1002/hsr2.282

Cited by 14 publications

(6 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to regular chemotherapy or donor lymphocyte treatments, cell therapy is shown to be more effective in controlling the disease, especially in the long term . The efficacy of cell transplants can be influenced by some factors, such as anoikis, physical pressures prior and post-transplantation, oxygen and nutrient shortages, and immune system response. , Other notable challenges are poor engraftment, potential contaminations and impurities, and source scarcity. , Considering these challenges, some of the main barriers could be addressed by employing biomaterials in personalized cell therapy . In the following sections, we will review the technologies for cell-biomaterials fabrication and transplantation and the benefit of these constructs.…”

Section: Challenges In Therapeutic Cell Transplantationmentioning

confidence: 99%

Cell Encapsulation and 3D Bioprinting for Therapeutic Cell Transplantation

Samadi¹,

Moammeri

Pourmadadi

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The promise of cell therapy has been augmented by introducing biomaterials, where intricate scaffold shapes are fabricated to accommodate the cells within. In this review, we first discuss cell encapsulation and the promising potential of biomaterials to overcome challenges associated with cell therapy, particularly cellular function and longevity. More specifically, cell therapies in the context of autoimmune disorders, neurodegenerative diseases, and cancer are reviewed from the perspectives of preclinical findings as well as available clinical data. Next, techniques to fabricate cellbiomaterials constructs, focusing on emerging 3D bioprinting technologies, will be reviewed. 3D bioprinting is an advancing field that enables fabricating complex, interconnected, and consistent cell-based constructs capable of scaling up highly reproducible cell-biomaterials platforms with high precision. It is expected that 3D bioprinting devices will expand and become more precise, scalable, and appropriate for clinical manufacturing. Rather than one printer fits all, seeing more application-specific printer types, such as a bioprinter for bone tissue fabrication, which would be different from a bioprinter for skin tissue fabrication, is anticipated in the future.

show abstract

Section: Challenges In Therapeutic Cell Transplantationmentioning

confidence: 99%

Cell Encapsulation and 3D Bioprinting for Therapeutic Cell Transplantation

Samadi¹,

Moammeri

Pourmadadi

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Secondly, there is always a risk of graft‐vs‐host disease and complications arising from undergoing immunosuppressive regimens for transplantation. For many patients, autologous transplantation combined with gene editing is therefore preferred strategy over allogeneic transfer 89 and CRISPR technologies have further shifted the balance toward genetic correction of autologous HSCs. Previous efforts to correct genetic disorders for autologous HCT used viral vectors for gene therapy.…”

Section: Current Clinical Applications Of Crispr‐edited Hscsmentioning

confidence: 99%

A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic

Worthington

Forsberg

2022

American J Hematol

View full text Add to dashboard Cite

Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas genome engineering has emerged as a powerful tool to modify precise genomic sequences with unparalleled accuracy and efficiency. Major advances in CRISPR technologies over the last 5 years have fueled the development of novel techniques in hematopoiesis research to interrogate the complexities of hematopoietic stem cell (HSC) biology. In particular, high throughput CRISPR based screens using various “flavors” of Cas coupled with sequencing and/or functional outputs are becoming increasingly efficient and accessible. In this review, we discuss recent achievements in CRISPR‐mediated genomic engineering and how these new tools have advanced the understanding of HSC heterogeneity and function throughout life. Additionally, we highlight how these techniques can be used to answer previously inaccessible questions and the challenges to implement them. Finally, we focus on their translational potential to both model and treat hematological diseases in the clinic.

show abstract

“…In countries with a National Bone Marrow (BM) Donors Registry, finding an 8/8 or 10/10 compatible URD can be reduced by several months, having a positive effect on the treatment and quality of life of patients ( 5 – 13 ). In the absence of a National BM Donors Registry, searching for compatible URD can take a longer time, leading medical treatment toward alternative sources of hematopoietic stem cells such as haploidentical transplant or umbilical cord blood (UCB) units, which are associated with higher risks of graft-versus-host disease (GVHD), graft failure or transplant-related death (TRM) ( 14 – 18 ). Since 2018, the Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud (IDCBIS) has been promoting the creation of a National BM Donor Registry in Colombia to provide hematopoietic stem cells from URD to the country’s transplant centers, ultimately shortening the waiting time of patients requiring HSC transplants.…”

Section: Introductionmentioning

confidence: 99%

Distributions of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 alleles and haplotype frequencies of 1763 stem cell donors in the Colombian Bone Marrow Registry typed by next-generation sequencing

Hernández¹,

Páez-Gutiérrez²,

Ardón³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The HLA compatibility continues to be the main limitation when finding compatible donors, especially if an identical match is not found within the patient’s family group. The creation of bone marrow registries allowed a therapeutic option by identifying 10/10 compatible unrelated donors (URD). However, the availability and frequency of haplotypes and HLA alleles are different among ethnic groups and geographical areas, increasing the difficulty of finding identical matches in international registries. In this study, the HLA-A, -B, -C, -DRB1, and -DQB1 loci of 1763 donors registered in the Colombian Bone Marrow Registry were typed by next-generation sequencing. A total of 52 HLA-A, 111 HLA-B, 41 HLA-C, 47 HLA-DRB1, and 20 HLA-DQB1 alleles were identified. The 3 most frequent alleles for each loci were A*24:02g (20,8%), A*02:01g (16,1%), A*01:01g (7.06%); B*35:43g (7.69%), B*40:02g (7.18%), B*44:03g (6.07%); C*04:01g (15.40%), C*01:02g (10.49%), C*07:02g (10.44%); DRB1*04:07g (11.03%), DRB1*07:01g (9.78%), DRB1*08:02g (6.72%); DQB1*03:02g (20.96%), DQB1*03:01g (17.78%) and DQB1*02:01g (16.05%). A total of 497 HLA-A-C-B-DRB1-DQB1 haplotypes were observed with a frequency greater than or equal to 0.05% (> 0.05%); the haplotypes with the highest frequency were A*24:02g~B*35:43g~C*01:02g~DQB1*03:02g~DRB1*04:07g (3.34%), A*29:02g~B*44:03g~C*16:01g~DQB1*02:01g~DRB1*07:01g (2.04%), and A*01:01g~B*08:01g~C*07:01g~DQB1*02:01g~DRB1*03:01g (1.83%). This data will allow the new Colombian Bone Marrow Donor Registry to assess the genetic heterogeneity of the Colombian population and serve as a tool of interest for future searches of unrelated donors in the country.

show abstract

A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes

Cited by 14 publications

References 83 publications

Cell Encapsulation and 3D Bioprinting for Therapeutic Cell Transplantation

Cell Encapsulation and 3D Bioprinting for Therapeutic Cell Transplantation

A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic

Distributions of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 alleles and haplotype frequencies of 1763 stem cell donors in the Colombian Bone Marrow Registry typed by next-generation sequencing

Contact Info

Product

Resources

About